EP Patent

EP3813798A1 — Exosome extracellular vesicles and methods of use

Assigned to AstraZeneca AB · Expires 2021-05-05 · 5y expired

What this patent protects

Exosomes comprising a modified RNA are disclosed. Aspects of the disclosure further relate to methods and compositions for using exosomes comprising a modified RNA. In certain aspects, the exosomes disclosed herein may be useful in delivering a modified RNA to a cell. In certain …

USPTO Abstract

Exosomes comprising a modified RNA are disclosed. Aspects of the disclosure further relate to methods and compositions for using exosomes comprising a modified RNA. In certain aspects, the exosomes disclosed herein may be useful in delivering a modified RNA to a cell. In certain aspects, the exosomes disclosed herein may be useful in treating or preventing a disorder in a subject. Methods and compositions for producing the disclosed exosomes are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3813798A1
Jurisdiction
EP
Classification
—
Expires
2021-05-05
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.